(Q35097970)

6 August 2017

1 reference

title

Progress in the chemotherapy of metastatic cancer of the urinary tract (English)

1 reference

6 August 2017

1 reference

Derek Raghavan

1

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 April 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

97

1 reference

6 August 2017

issue

8 Suppl

1 reference

6 August 2017

page(s)

2050-2055

1 reference

Clonal analysis of a bladder cancer cell line: an experimental model of tumour heterogeneity

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11280

The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11280

7 January 2021

Biology and management of bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11280

7 January 2021

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11280

7 January 2021

Metastases from transitional cell carcinoma of urinary bladder

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11280

7 January 2021

Treatment of carcinomatous meningitis from transitional cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11280

7 January 2021

Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11280

7 January 2021

Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11280

7 January 2021

A phase II study of gemcitabine plus cisplatin chemotherapy in advanced bilharzial bladder carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11280

7 January 2021

The chemotherapy of urologic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11280

7 January 2021

Chemotherapy of Metastatic Bladder Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11280

7 January 2021

Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11280

7 January 2021

Comparative activity and toxicity of cis-diamminedichloroplatinum (DDP) and a combination of doxorubicin, cyclophosphamide, and DDP in disseminated transitional cell carcinomas of the urinary tract

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11280

7 January 2021

Phase III comparison of cisplatin alone versus cisplatin, doxorubicin and cyclophosphamide in the treatment of bladder (urothelial) cancer: a Southeastern Cancer Study Group trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11280

7 January 2021

A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11280

7 January 2021

Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11280

7 January 2021

Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11280

7 January 2021

Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11280

7 January 2021

MVAC for bladder cancer: time to move forward again

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11280

7 January 2021

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11280

7 January 2021

Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11280

7 January 2021

Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11280

7 January 2021

Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11280

7 January 2021

Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11280

7 January 2021

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11280

7 January 2021

Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11280

7 January 2021

Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11280

7 January 2021

Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11280

7 January 2021

Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11280

7 January 2021

Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11280

7 January 2021

Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11280

7 January 2021

Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11280

7 January 2021

Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11280

7 January 2021

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11280

7 January 2021

Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11280

7 January 2021

Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11280

7 January 2021

Identifiers

DOI

10.1002/CNCR.11280

1 reference

6 August 2017

1 reference